Combining Anti-VEGF and Anti-EGFR Antibodies: Irinotecan and Cetuximab With or Without Ramucirumab as a Second-Line Treatment for Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)
J. Natl. Cancer Inst 2024 Sep 01;116(9)1487-1494, HS Hochster, P Catalano, M Weitz, EP Mitchell, D Cohen, PJ O'Dwyer, BA Faller, JS Kortmansky, MH O'Hara, SM Kricher, J Lacy, HJ Lenz, U Verma, AB BensonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.